Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma: Unsatisfactory for Clinical Use, but Some Less So?

Ivo Abraham^{1

2

3

4}, Clara Curiel-Lewandrowski^{2

5}

Affiliations

¹ Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson.
² University of Arizona Cancer Center, Tucson.
³ College of Pharmacy, Department of Pharmacy Practice and Science, University of Arizona, Tucson.
⁴ Department of Family and Community Medicine, College of Medicine, Department of Dermatology, University of Arizona, Tucson.
⁵ Division of Dermatology, Department of Medicine, College of Medicine, University of Arizona, Tucson.

Editorial

Ivo Abraham et al. JAMA Dermatol. 2018.

. 2018 Dec 1;154(12):1391-1392.

doi: 10.1001/jamadermatol.2018.3940.

Ivo Abraham^{1

2

3

4}, Clara Curiel-Lewandrowski^{2

5}

¹ Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson.
² University of Arizona Cancer Center, Tucson.
³ College of Pharmacy, Department of Pharmacy Practice and Science, University of Arizona, Tucson.
⁴ Department of Family and Community Medicine, College of Medicine, Department of Dermatology, University of Arizona, Tucson.
⁵ Division of Dermatology, Department of Medicine, College of Medicine, University of Arizona, Tucson.

No abstract available

Comment on

Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
Roscher I, Falk RS, Vos L, Clausen OPF, Helsing P, Gjersvik P, Robsahm TE. Roscher I, et al. JAMA Dermatol. 2018 Apr 1;154(4):428-434. doi: 10.1001/jamadermatol.2017.6428. JAMA Dermatol. 2018. PMID: 29516080 Free PMC article.